ID Now

The Abbott ID NOW™ STREP A 2 assay demonstrates exceptional performance for detecting S. pyogenes in non-pharyngeal specimens, yielding 99.2% sensitivity and 100% specificity. Despite its current limitation to pharyngeal use, these findings confirm the assay is a highly reliable tool for the rapid diagnosis of skin and soft tissue infections (SSTIs).

"While the Abbott ID NOW system demonstrates reliable COVID-19 detection, the SG method emerges as a superior collection technique to NP swabs, offering enhanced diagnostic accuracy and improved comfort for test takers. This study underscores the importance of selecting appropriate collection methods to ensure accurate and efficient COVID-19 testing."

" Although relatively few patients in this study had maximum scores on the FeverPAIN and McIsaac scoring, the addition of POCT was shown to alter antibiotic prescribing decisions in a significant number of patients, supporting the use of Abbott ID NOW point of care testing to reduce antibiotic prescribing. Larger studies are required to confirm these results and explore the health economic aspects and potential impacts on health inequalities."

The study confirms that the Abbott ID NOW™ isothermal assay shows high concordance (0.949) with conventional RT-PCR for SARS-CoV-2 detection. By reducing the turnaround time from 3 hours to just 13 minutes, it serves as an efficient and reliable tool for screening HSC donors, particularly when rapid clinical decision-making is essential.

Rapid molecular POCT significantly improves antibiotic stewardship by reducing prescriptions by 55-65%. Despite higher costs and longer appointments, the technology proved more reliable than clinical scoring and was highly valued by both patients and staff, making it a powerful tool for improving the quality of care in primary settings.

SARS-CoV-2 mutations can cause false-negative results by altering proprietary NAAT target sites. This study identified 29 novel mutations that compromise detection in commercial tests like Xpert and Cobas, with the N gene being the most vulnerable. The findings prove that ongoing genetic surveillance and manufacturer transparency are vital for diagnostic quality assurance. A collaborative framework between labs and industry is essential to ensure tests remain accurate as the virus evolves.

"These survey findings helped us to understand the strength and efficiency of laboratories in India in setting up new assays during a crisis time. Based on our findings, we propose to connect this network in a sustained manner to efficiently utilize the existing platforms to adapt to future pandemics."

The study concludes that the Abbott ID NOW™ assay is an effective tool for rapid COVID-19 detection in outbreak settings, though its sensitivity (86%) is lower than standard RT-PCR. To bridge this gap, the researchers recommend a "do not discard" workflow: by re-testing the residual nasal swab (rNS) via RT-PCR after its use in the ID NOW™ device, diagnostic sensitivity increased to 93%. This approach provides immediate, actionable results while ensuring high-accuracy confirmation and material for genomic sequencing without requiring additional, invasive patient sampling.

This study confirms that the Abbott ID NOW assay is most effective for symptomatic individuals, achieving 92.5% sensitivity. However, performance drops significantly to 73.9% in asymptomatic populations, likely due to lower viral loads. While the device maintains excellent specificity (>99%) and outperforms rapid antigen tests, its reliability for screening asymptomatic groups is limited. Additionally, using combined swabs offered no diagnostic advantage over standard methods.

This study confirms that natural spring water gargle is a reliable, noninvasive alternative to traditional swabs for SARS-CoV-2 detection using the Abbott ID NOW assay.The method is highly effective for symptomatic patients (95.2% agreement) and shows 100% sensitivity in cases with higher viral loads. Performance is optimized by adding 500 µl of the specimen directly to the test and avoiding heat pretreatment. Due to its high patient acceptability, this method is well-suited for frequent screening and rapid point-of-care diagnostics.

"In patients with suspected influenza in the emergency department, although rapid NAAT [ID NOW Influenza A&B, Abbott] and RAT [BD Veritor System for Rapid Detection of Flu A + B, BD] demonstrated good agreement, the cases that tested positive by the rapid NAAT but negative by the RAT were significantly more frequent. This suggests that rapid NAAT may be a more suitable diagnostic tool in the emergency department, as rapid NAAT can help avoid false negatives, enable timely antiviral treatment, and improve clinical decision-making within the critical treatment window."

"Compared to antigen-based lateral flow assays [BD Veritor™ Plus System, Sofia® Strep A+ Fluorescent Immunoassay, and Sekisui Diagnostic OSOM® Strep A test for GAS detection], the molecular ID Now Strep A 2 assay demonstrated a lower LoD, which translates into higher sensitivity. In a clinical setting, this could enable detection of samples with a lower bacterial load that could be missed by low-sensitivity LFAs."

The Pluslife Mini Dock, powered by RHAM technology, offers a highly accurate and rapid alternative to traditional RT-PCR for SARS-CoV-2 detection. With a PPA of 99.00% and an NPA of 100.00%, it demonstrated superior analytical performance compared to Abbott ID Now and Cepheid GeneXpert IV, particularly by minimizing invalid results. Its ability to reliably detect various variants (Delta/Omicron) and maintain high sensitivity makes it an excellent Point-of-Care solution for interrupting transmission chains.

This study confirms that post-market surveillance is essential for maintaining diagnostic reliability as viruses evolve. Evaluation of six widely used COVID-19 point-of-care tests [four rapid antigen tests (Abbott Panbio, BTNX Rapid Response, SD Biosensor, and Quidel QuickVue) and two molecular tests (Abbott ID NOW and Lucira Check IT)] demonstrated that both rapid antigen and molecular assays maintained consistent clinical performance across various SARS-CoV-2 variants, including Omicron XBB.1.5. These findings validate the continued use of decentralized testing and reinforce confidence in these tools despite the emergence of new viral mutations.

"POCTs [cobas SARS-CoV-2 & Influenza A/B assay with the cobas Liat RT-qPCR system (Roche Diagnostics), ID NOW COVID-19 and COVID-19 2.0 (Abbott), and SARS-CoV-2 Rapid Antigen Test (RAT) (Roche Diagnostics)] enable the detection of SARS-CoV-2 RNA or antigen in BAL fluid samples and may provide additional information to decide if donor lungs are suitable for transplantation. Detection of respiratory pathogens with POCTs at the time of donor lung procurement is a potential strategy to increase safety in LTx by preventing iatrogenic transmission and severe postoperative infections."

This multicenter study investigates whether rapid nucleic acid tests [Abbott ID NOW STREP A2] are sensitive enough to detect Group A Streptococcus in saliva instead of traditional throat swabs [EXACTO PRO STREPTATEST, lateral flow assay, comparator test]. By evaluating 800 children in primary care, the researchers aim to provide a more comfortable and non-invasive diagnostic method. If the salivary NAAT reaches the required 80% sensitivity, it could simplify strep throat testing and improve antibiotic stewardship in clinical practice.

"Fast track, DNA Technology, QiaPrep, Xpress SARS-CoV-2 and ID Now showed good diagnostic performance. Positive RAD rule in SARS-CoV-2 infection, however negative results should be correlated with clinical condition and molecular testing."

"All of the assays [Idylla™ SARS-CoV-2 and the Idylla™ SARS-CoV2/Flu/RSV, and two isothermal amplification assays, the ID NOW COVID and the ID NOW influenza A & B 2] are suitable for testing patients with respiratory symptoms. False negatives should be considered, and the test should be repeated regarding the context."

POC systems [Accula (Mesa Biotech), BioFire Respiratory Panel 2.1-EZ (BioMerieux), cobas SARS-CoV-2 (Roche Molecular Systems), Cue COVID-19 Test (Cue Health), Detect Covid-19 Test (Detect Inc.), ID NOW (Abbott), Lucira Check-It / All-In-One (Lucira Health), Talis One (Talis Biomedical), Visby (Visby Medical), Xpert Xpress (Cepheid)] significantly reduce SARS-CoV-2 detection times by bypassing the logistical delays of traditional RT-PCR. Among FDA-authorized molecular tests, the Xpert Xpress demonstrates superior clinical performance, while the ID NOW lags in sensitivity. Although the Cue COVID-19 Test leads the OTC market in accuracy, its high cost and the general lack of independent literature for many systems remain notable drawbacks. The pandemic-driven shift toward rapid, discrete self-testing has established a foundation for broader applications, such as home-based screening for sexually transmitted diseases. However, the future success of these technologies depends on lowering costs without compromising sensitivity, ensuring reliability for untrained users in uncontrolled environments, and developing multiplex devices capable of detecting multiple pathogens simultaneously.

The Abbott ID NOW™ COVID-19 2.0 is a highly effective point-of-care (POC) molecular test, demonstrating a 91.7% PPA and 98.4% NPA in symptomatic patients. Its accuracy is particularly high (99.4%) at lower cycle thresholds (Ct ≤30), where viral loads are greatest. Delivering results in under 12 minutes, it serves as a rapid, reliable alternative to lab-based RT-PCR, enabling immediate clinical decisions and infection control in resource-limited or acute settings.

The 2023 External Quality Assessment (EQA) conducted by the Tokyo Metropolitan Government highlights that while SARS-CoV-2 nucleic acid amplification tests in clinical settings maintain a high overall accuracy (above 93%), significant challenges remain regarding user error. Because many of these tests are performed by non-specialists using point-of-care (POCT) instruments, discrepancies often arise from protocol deviations rather than equipment failure. The study concludes that ongoing EQA and targeted technical support are essential to minimize procedural errors - such as improper sample handling - and to ensure the long-term reliability of diagnostic testing in primary care environments.

While self-collected buccal swabs are significantly less painful and offer excellent specificity (99.3%), their sensitivity is limited (58.5%) compared to nasopharyngeal RT-PCR. Performance is strongest in patients with high viral loads and early symptom onset. Despite the lower sensitivity, the ease of collection may improve testing acceptance in pediatric settings, provided clinicians account for the risk of false negatives.

The ID NOW™ 2.0 provides a rapid and reliable alternative to laboratory RT-PCR, delivering results in just 12 minutes. With 100% sensitivity for samples with Ct values < 35 and an overall specificity of 100%, it is highly effective for clinical screening. Despite minor sensitivity trade-offs at very low viral loads, its speed and accuracy make it an ideal point-of-care tool for managing the ongoing COVID-19 landscape.

"ID NOW offers a valid diagnostic tool to detect SARS-CoV-2, performing comparably to a reference laboratory-based assay which takes longer to provide results."

The ID NOW™ COVID-19 2.0 assay showed excellent diagnostic accuracy with 99.5% overall agreement (97.6% PPA, 100% NPA) compared to RT-PCR. Performance remained consistently high regardless of the time since symptom onset, making it a reliable, rapid alternative for immediate clinical decision-making.

"This data highlights the rise and diversification of SARS-CoV-2 omicron variants over the course of 2022 and demonstrate that each of the 5 tested assays can detect the breadth of omicron variants circulating globally."

"Due to its ease of use and speed of result, ID-NOW™ is a suitable diagnostic tool for prompt assessment of a patient's infectivity. If, despite the negative ID-NOW™ result, the patient has symptoms of COVID-19, it is advised to perform a classic PCR test for SARS-CoV-2."

"In summary, rapid testing has become an important tool in our COVID-19 diagnostic toolkit. It is now deployed within MUSC Health system as a true POC test for rapid identification and isolation of infected individuals, appropriate use of personal protective equipment, and initiation of special workflows required for emergency care and in time-sensitive outpatient settings. Future population-based outcome studies are needed to evaluate the effectiveness of this approach in enabling equal access to care and improving healthcare delivery to the communities across our health network."

"Assay performance can be modeled as dependent on viral load, fit using laboratory bench study results, and adjusted to account for direct-specimen testing. When using nasopharyngeal specimens, direct testing on Abbott ID NOW and VTM testing on DiaSorin Simplexa have similar performance."

"Our study found that sensitivity of the ID NOW test is lower but specificity is high. Due to the ease of use and shortest result time for detecting COVID-19, ID NOW can be used as a rapid point of care test for diagnosis of COVID-19 with samples from symptomatic patients at high viral load, patients coming to emergency department, but there is the possibility that ID NOW may miss infections in the asymptomatic infected population with low viral load. However negative results should be correlated with clinical symptoms and radiological evidence of COVID-19."

"This study confirmed the superior sensitivity of Abbott's Strep A2 NAAT over RADT. Given the Belgian guidelines against routine antibiotic treatment for pharyngitis and considering local treatment recommendations and cost, implementing NAAT for GAS detection in Belgian laboratories is less beneficial. However, the role of NAAT in supporting antimicrobial stewardship by ensuring appropriate antibiotic use remains significant."